Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Updated daily

Drug recalls

Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.

Class IITerminatedMay 7, 2014Fluoxetine CapsulesChemical Contamination: The recalling firm received notice that their supplier is recalling capsules due to complaints of capsules having an unusual odor.Legacy Pharmaceutical Packaging · D-1279-2014Class ITerminatedMay 7, 2014Lidocaine HCl InjectionPresence of Particulate Matter- Confimed customer complaint of particulates embedded in glass container and in contact with product solution.Hospira Inc. · D-1278-2014Class ITerminatedMay 7, 2014Adipotrim XTMarketed Without an Approved NDA/ANDA: FDA lab results found undeclared API Fluoxetine in this dietary supplement.Deseo Rebajar · D-1277-2014Class ITerminatedMay 7, 2014Dianeal PD-2 Peritoneal Dialysis Solution with 1.5% DextroseNon-Sterility: Complaints of leaks and particulate matter identified as mold in the solution bag and the overpouch.Baxter Healthcare Corp. · D-1276-2014Class ITerminatedMay 7, 2014Hyperlyte CRPresence of Particulate Matter: B. Braun Medical Inc. is recalling several injectable products due to visible particulate matter found in reserve sample units.B. Braun Medical Inc · D-1275-2014Class ITerminatedMay 7, 2014ProcalAminePresence of Particulate Matter: B. Braun Medical Inc. is recalling several injectable products due to visible particulate matter found in reserve sample units.B. Braun Medical Inc · D-1274-2014Class ITerminatedMay 7, 2014TrophAminePresence of Particulate Matter: B. Braun Medical Inc. is recalling several injectable products due to visible particulate matter found in reserve sample units.B. Braun Medical Inc · D-1273-2014Class ITerminatedMay 7, 201415% Amino Acids Injection PBP GlassPresence of Particulate Matter: B. Braun Medical Inc. is recalling several injectable products due to visible particulate matter found in reserve sample units.B. Braun Medical Inc · D-1272-2014Class ITerminatedMay 7, 20146.9% FreAmine HBCPresence of Particulate Matter: B. Braun Medical Inc. is recalling several injectable products due to visible particulate matter found in reserve sample units.B. Braun Medical Inc · D-1271-2014Class ITerminatedMay 7, 20140.9 % Sodium Chloride Injection USPPresence of Particulate Matter: B. Braun Medical Inc. is recalling several injectable products due to visible particulate matter found in reserve sample units.B. Braun Medical Inc · D-1270-2014Class ITerminatedMay 7, 2014Cefazolin for Injection USP and Dextrose Injection USPPresence of Particulate Matter: B. Braun Medical Inc. is recalling several injectable products due to visible particulate matter found in reserve sample units.B. Braun Medical Inc · D-1269-2014Class ITerminatedMay 7, 2014Cefazolin for Injection USP and Dextrose Injections USPPresence of Particulate Matter: B. Braun Medical Inc. is recalling several injectable products due to visible particulate matter found in reserve sample units.B. Braun Medical Inc · D-1268-2014Class ITerminatedMay 7, 2014Cefepime for Injections USP and Dextrose Injection USPPresence of Particulate Matter: B. Braun Medical Inc. is recalling several injectable products due to visible particulate matter found in reserve sample units.B. Braun Medical Inc · D-1267-2014Class ITerminatedMay 7, 2014Ceftriaxone for Injection and Dextrose InjectionPresence of Particulate Matter: B. Braun Medical Inc. is recalling several injectable products due to visible particulate matter found in reserve sample units.B. Braun Medical Inc · D-1266-2014Class ITerminatedMay 7, 20140.9 % Sodium Chloride Injection USP in PAB 50 mL partial fill in 100 mL PAB ContainerPresence of Particulate Matter: B. Braun Medical Inc. is recalling several injectable products due to visible particulate matter found in reserve sample units.B. Braun Medical Inc · D-1265-2014Class ITerminatedMay 7, 2014Cefoxitin for Injection and Dextrose InjectionPresence of Particulate Matter: B. Braun Medical Inc. is recalling several injectable products due to visible particulate matter found in reserve sample units.B. Braun Medical Inc · D-1264-2014Class ITerminatedMay 7, 2014Human Chorionic GonadotropinLabeling: Label Error on Declared Strength; Firm states that erroneous potency information was found on the label.Medisca Inc. · D-1263-2014Class IITerminatedMay 7, 2014SevofluraneFailed pH Specifications: product was too acidic.Piramal Critical Care, Inc. · D-1262-2014Class IITerminatedMay 7, 2014Polidocanol 3% SolutionPresence of Particulate MatterJohn W Hollis Inc · D-1260-2014Class IIITerminatedMay 7, 2014Polidocanol 1% SolutionLabeling: Incorrect Expiration Date; Expiration date is earlier than listed on vial.John W Hollis Inc · D-1259-2014Class IIITerminatedMay 7, 2014Papaverine 60 mgLabeling: Incorrect Expiration Date; Expiration date is earlier than listed on vial.John W Hollis Inc · D-1258-2014Class IITerminatedMay 7, 2014Phosphatidylcholine Solution for InjectionLabeling: Incorrect Expiration Date; Expiration date is earlier than listed on vial.John W Hollis Inc · D-1257-2014Class IITerminatedApr 30, 2014Potassium Chloride for Inj. ConcentratePresence of Particulate; red and black particulate within the solution and embedded within the plastic vial identified as iron oxideHospira Inc. · D-1261-2014Class IITerminatedApr 30, 2014Non-Drowsy 24 Hour Formula Allergy Relief and Nasal DecongestantDefective Container: An unacceptable level of blister defects have been identified in Loratadine and Pseudoephedrine Sulfate Extended Release Tablets, 10 mg/240 mg.Ohm Laboratories, Inc. · D-1256-2014Class IIITerminatedApr 30, 2014Oxandrolone TabletsLabeling: Missing Label; Three cases of product (total of 36 bottles) were packaged without the primary label on the bottle. The cases were, however, packaged in the...Upsher Smith Laboratories, Inc. · D-1255-2014Class IIITerminatedApr 30, 2014Day Time Cold & FluSubpotent Drug: Phenylephrine component is subpotent.P&L Developments, LLC · D-1254-2014Class IITerminatedApr 30, 2014Tikosyn¿Presence of Foriegn Tablets/Capsules: A single Tikosyn¿ (dofetilide) 250 mcg capsule was discovered in one bottle of Tikosyn¿ (dofetilide) 500 mcg (0.5 mg).Pfizer Inc. · D-1253-2014Class ITerminatedApr 30, 2014GlycopyrrolateNon-Sterility: One lot of Glycopyrrolate solution for injection was found to be contaminated with Bacillus thuringiensis.Brookfield Prescription Center Inc · D-1252-2014Class ITerminatedApr 30, 2014VPRIV¿ (velaglucerase alfa for injection)Presence of Particulate Matter; Particulates identified as stainless steel and barium sulfate.Shire Human Genetic Therapies, Inc. · D-1251-2014Class ITerminatedApr 30, 2014XIYOUJI QINGZHI CAPSULEMarketed without an Approved NDA/ANDA: Products found to contain undeclared sibutramine. Sibutramine was removed from the U.S. market for safety reasons, making these...Dolphin Intertrade Corporation · D-1250-2014Class ITerminatedApr 30, 2014JaDera, 100% Natural Weight Loss SupplementMarketed without an Approved NDA/ANDA: Products found to contain undeclared sibutramine. Sibutramine was removed from the U.S. market for safety reasons, making these...Dolphin Intertrade Corporation · D-1249-2014Class ITerminatedApr 30, 2014RezzRX capsulesMarketed Without an Approved NDA/ANDA: Fossil Fuel Products, is recalling RezzRX due to undeclared hydroxylthiohomosildenafil and aminotadalafil.Fossil Fuel Products, LLC · D-1248-2014Class IIITerminatedApr 30, 2014Nicorette Lozenge and NicoDerm CQFailed Lozenge Specifications; Lozenges are overly thick, overly soft, and sub and superpotent.GlaxoSmithKline Consumer Healthcare; dba-GlaxoSmithKline · D-1247-2014Class IIITerminatedApr 30, 2014NicoretteFailed Lozenge Specifications; Lozenges are overly thick, overly soft, and sub and superpotent.GlaxoSmithKline Consumer Healthcare; dba-GlaxoSmithKline · D-1246-2014Class IIITerminatedApr 30, 2014NicoretteFailed Lozenge Specifications; Lozenges are overly thick, overly soft, and sub and superpotent.GlaxoSmithKline Consumer Healthcare; dba-GlaxoSmithKline · D-1245-2014Class IIITerminatedApr 30, 2014Nicorette LozengeFailed Lozenge Specifications; Lozenges are overly thick, overly soft, and sub and superpotent.GlaxoSmithKline Consumer Healthcare; dba-GlaxoSmithKline · D-1244-2014Class IIITerminatedApr 30, 2014Nicotine polacrilex lozengeFailed Lozenge Specifications; Lozenges are overly thick, overly soft, and sub and superpotent.GlaxoSmithKline Consumer Healthcare; dba-GlaxoSmithKline · D-1243-2014Class IIITerminatedApr 30, 2014Nicotine polacrilex lozengeFailed Lozenge Specifications; Lozenges are overly thick, overly soft, and sub and superpotent.GlaxoSmithKline Consumer Healthcare; dba-GlaxoSmithKline · D-1242-2014Class IIITerminatedApr 30, 2014Nicotine polacrilex lozengeFailed Lozenge Specifications; Lozenges are overly thick, overly soft, and sub and superpotent.GlaxoSmithKline Consumer Healthcare; dba-GlaxoSmithKline · D-1241-2014Class IIITerminatedApr 30, 2014Nicotine polacrilex lozengeFailed Lozenge Specifications; Lozenges are overly thick, overly soft, and sub and superpotent.GlaxoSmithKline Consumer Healthcare; dba-GlaxoSmithKline · D-1240-2014

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.